- Home
- PAYC vs ROIV Comparison
PAYC vs ROIV Comparison
Compare PAYC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYC
- ROIV
- Stock Information
- Founded
- PAYC 1998
- ROIV 2014
- Country
- PAYC United States
- ROIV United Kingdom
- Employees
- PAYC N/A
- ROIV N/A
- Industry
- PAYC Computer Software: Prepackaged Software
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- PAYC Technology
- ROIV Health Care
- Exchange
- PAYC Nasdaq
- ROIV Nasdaq
- Market Cap
- PAYC 14.6B
- ROIV 7.8B
- IPO Year
- PAYC 2014
- ROIV N/A
- Fundamental
- Price
- PAYC $224.07
- ROIV $11.40
- Analyst Decision
- PAYC Hold
- ROIV Buy
- Analyst Count
- PAYC 11
- ROIV 4
- Target Price
- PAYC $230.00
- ROIV $17.50
- AVG Volume (30 Days)
- PAYC 660.7K
- ROIV 7.9M
- Earning Date
- PAYC 07-30-2025
- ROIV 08-07-2025
- Dividend Yield
- PAYC 0.65%
- ROIV N/A
- EPS Growth
- PAYC N/A
- ROIV N/A
- EPS
- PAYC 7.02
- ROIV N/A
- Revenue
- PAYC $1,913,800,000.00
- ROIV $29,053,000.00
- Revenue This Year
- PAYC $10.03
- ROIV $3.28
- Revenue Next Year
- PAYC $9.22
- ROIV $156.84
- P/E Ratio
- PAYC $31.38
- ROIV N/A
- Revenue Growth
- PAYC 9.87
- ROIV N/A
- 52 Week Low
- PAYC $140.69
- ROIV $8.73
- 52 Week High
- PAYC $267.76
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- PAYC 35.90
- ROIV 54.55
- Support Level
- PAYC $222.20
- ROIV $10.71
- Resistance Level
- PAYC $236.24
- ROIV $11.58
- Average True Range (ATR)
- PAYC 6.25
- ROIV 0.29
- MACD
- PAYC -0.21
- ROIV 0.00
- Stochastic Oscillator
- PAYC 19.35
- ROIV 62.16
About PAYC Paycom Software Inc.
Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.